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OLIVE Registry*
Matthew T. Menard, MDT he report by Iida et al. (1) in this issue ofJACC: Cardiovascular Interventions on theintermediate results of the OLIVE (A Pro-
spective, Multi-Center, Three-Year Follow-Up Study
on Endovascular Treatment for Infra-Inguinal Vessel
in Patients With Critical Limb Ischemia) Registry is
an informative expansion of an earlier accounting
of the 1-year outcomes by the same investigators
(2). The study cohort comprised 314 Japanese pa-
tients with critical limb ischemia (CLI) who were
prospectively followed after undergoing endovascu-
lar treatment (EVT). There was an impressive 95%
retention of the patients originally enrolled in the
registry over the 3 years of the current report. The
primary outcome of the study was amputation-free
survival, whereas secondary measures included ma-
jor adverse limb event (MALE), wound-free survival,
and wound recurrence. The OLIVE registry restricts
its scope to endovascular therapy and has no com-
parative surgical arm.SEE PAGE 1493The demographics of the registry cohort reﬂect
the challenging clinical patterns of comorbid disease
typically seen in CLI patients. Of particular note
were the high rates of diabetes mellitus (71%), renal
failure (61%), and hemodialysis (52%) and the low
rate of statin use (26%). Nearly 90% of patients had
tissue loss, with 15% of patients classiﬁed as Ruth-
erford Class 6 and 20% as having multiple wounds.
The authors do not explain how almost 20% of the*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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tional Heart, Lung and Blood Institute.study cohort had a normal baseline ankle brachial
index (ABI), and only 6% had an ABI <0.4. This
discrepancy between the reported degree of
ischemia and the baseline hemodynamic status
leaves open the possibility of contamination of the
dataset by patients with nonischemic ulcers or
wounds, particularly important in light of the focus
given to wound healing and recurrence in the study.
Patients in the OLIVE registry had disease limited to
infrainguinal arteries, although how treatment of
common femoral arterial disease was considered was
not further elucidated. The surprisingly low rate of
patients ambulatory at baseline (12%) highlights both
the poor functional status and vulnerability of the
study cohort.
The major ﬁnding of the registry was a 3-year
amputation-free survival rate of 55%, a result com-
parable to that found in both the surgical and EVT
arms of the BASIL (Bypass versus Angioplasty in
Severe Ischemia of the Leg) trial (3). Rutherford Class
6 and end-stage renal disease were major predictors
of death or major amputation, consistent with an
ample literature previously indicating the signiﬁcant
inﬂuence of dialysis dependence and the extent of
disease on survival and limb salvage. That a low body
mass index was also predictive of a poor outcome is a
novel and intriguing result. While a breakdown
of MALE events was not provided, MALE outcomes
were also in the predicted range for this challenging
population.
The OLIVE investigators are to be applauded for
taking on the challenge of assessing wounds in the
registry. Reliably characterizing and tracking
ischemic leg wounds is difﬁcult, time-consuming,
and fraught with reporter bias, and for these rea-
sons, this important outcome metric is usually
missing from CLI studies. Wounds in the OLIVE
registry were managed by plastic surgeons and der-
matologists; vascular surgeons were conspicuous in
Menard J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5
Intermediate-Term Results of the OLIVE Registry S E P T E M B E R 2 0 1 5 : 1 5 0 3 – 5
1504their absence from the current study. The registry
incorporated independent assessment of photo-
graphed ulcers within the context of a wound core lab
for the ﬁrst year, while evaluation was less rigorously
left to the discretion of participating plastic surgeons
thereafter.
The goals of care for CLI are to relieve rest pain
and heal wounds, which, if achieved, give the pa-
tient the best chance of surviving with a preserved
limb. Along with questions about cumulative cost
and cost-effectiveness, it is the durability of suc-
cessful treatment that remains the most important
unresolved concern associated with EVT. Is perfu-
sion improved to the degree to heal a small ulcer, a
large ulcer, a heel ulcer—and prevent a recurrence
of that ulcer or a breakdown of a toe amputation
incision? Although the OLIVE registry does not
include desirable hemodynamic information or
insight into the nature of reinterventions, it does
provide relevant and valuable data on ulcer recur-
rence. Notably, in the described cohort, 43% of pa-
tients required a reintervention, and only 41% of
those who began the study with an ulcer were alive
and without an ulcer 3 years later. In comparison, of
those whose presenting symptom was rest pain, 70%
were alive without an ulcer at the 3-year follow-up
point. Few papers address the impact of different
treatment strategies on ulcer healing in CLI patients;
one that does, found surgical bypass associated with
a 2-fold improvement in wound resolution compared
with EVT (4).
As the authors acknowledge, there are ﬂaws in
the current study, some unique and some common
to all registries of this nature. The completeness of
the database in the absence of an objective auditing
mechanism, and hence the degree to which it re-
ﬂects real-world practice, remains unknown. The
absence of a surgical comparator may or may not
reﬂect a bias toward EVT for all patients regardless
of the anatomic pattern and initial clinical presen-
tation, thereby limiting its usefulness to those
whose practice patterns differ. The unavailability of
endovascular techniques typically used in North
American practice to OLIVE investigators (e.g.,
stenting as a bailout option in the event of a sub-
optimal tibial balloon angioplasty result) will likely
and reasonably be cited as a contributing factor in
the high rates of reintervention and ulcer recur-
rence seen. Taken together, however, the shift in
results from 1 to 3 years highlights the critical
importance of longer term data in accurately
judging the best treatment for complicated CLI
patients. Despite the collective limitations, theOLIVE registry appears to be a well-constructed
dataset that which adds needed information
beyond the short-term window that currently limits
much of the existing literature on CLI patients
receiving EVT.
The BEST-CLI (Best Endovascular vs. Best Surgical
Therapy in Patients With Critical Limb Ischemia)
study, a randomized, controlled trial currently
underway in the United States and Canada (5), will
hopefully shed additional much-needed light on the
treatment results of CLI patients. In the BEST-CLI
study, 2,100 patients in more than 120 centers will
be randomized to either open surgical bypass or EVT.
Nearly 800 investigators from all disciplines that
treat CLI in North America are participating. Patients
will be followed for more than 2 years, and a
comprehensive cost-effectiveness analysis will pro-
vide a more complete context for the ﬁnancial
impact of speciﬁc care rendered. Functional out-
comes will also be carefully studied in an effort to
more fully understand the effect of treatment on
quality of life and performance. As in the current
study, both initial and recurrent wounds will be
tracked and adjudicated.
There have been increasing and appropriate calls
for a more cooperative approach to CLI care,
modeled on the highly successful construct that has
become the current standard for the treatment of
cancer in the United States. In such a model, a range
of collaborating specialists with unique skill sets—
endovascular, surgical, podiatric, medical, diabetic,
plastic surgical—will demonstrate a willingness to
move beyond care rendered in isolation and at times
shadowed by specialty self-interest to that driven
solely by the best interests of the patient. This will
require those with lingering resistance to EVT to be
open to its evolving role. Just as signiﬁcantly, it
would require those who offer percutaneous treat-
ment with little awareness or consideration of the
ongoing importance of surgical therapy to be willing
to partner with their surgical colleagues. Deﬁning
the proper role of both surgical treatment and
EVT can only come from rigorous accounting of re-
sults, favorable or otherwise, from additional in-
vestigations, inclusive of institutional experience,
well-formulated registries, and randomized, con-
trolled trials such as BASIL-2, BASIL-3, and BEST-CLI
trials.
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